Biocad has plans to ship Remicade rival
Biocad has announced plans to begin shipping the firm’s biosimilar of Janssen’s Remicade (infliximab) to “global markets” towards the end of this year, or in early 2019.
Biocad has announced plans to begin shipping the firm’s biosimilar of Janssen’s Remicade (infliximab) to “global markets” towards the end of this year, or in early 2019.